COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Rentschler Biopharma Inc. named Manufacturer of the Year for Central Massachusetts23/10/2025
-   
  Instinct Science and Cornell University Hospital for Animals Modernize Veterinary Care with Instinct Treatment Plan23/10/2025
-   
  Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.23/10/2025
-   
  Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3ème trimestre 2025. Confirmation de l’ensemble des objectifs financiers 2025.23/10/2025
-   
  Avec Med4Cure, EUROAPI accélère l’innovation pharmaceutique au service de la souveraineté sanitaire23/10/2025
-   
  With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of health sovereignty23/10/2025
-   
  eteraflex connects and CliniExperts Announce Global Alliance to Redefine Clinical Research and Regulatory Services Delivery23/10/2025
-   
  ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference23/10/2025
-   
  Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference23/10/2025
-   
  Tango Therapeutics Announces $225 Million Financing23/10/2025
-   
  Cronos Group Inc. to Hold 2025 Third Quarter Earnings Conference Call on November 6, 202523/10/2025
-   
  Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results23/10/2025
-   
  Bionano Highlights Global Momentum Behind OGM at the 2025 Annual Meeting of the American Society of Human Genetics (ASHG) Meeting23/10/2025
-   
  Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer23/10/2025
-   
  Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)23/10/2025
-   
  Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast23/10/2025
-   
  Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review23/10/2025
-   
  LifeMD to Report Third Quarter 2025 Financial Results on November 623/10/2025
-   
  Collegium to Report Third Quarter 2025 Financial Results on November 6, 202523/10/2025
Pages